janssen science wordmark

IMBRUVICA®

(ibrutinib)

IMBRUVICA® (ibrutinib)

 

Janssen Biotech, Inc. and Pharmacyclics, Inc. entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. For medical information on IMBRUVICA (ibrutinib), please contact Pharmacyclics Medical Information at www.pharmacyclicsmedinfo.com or call 1-877-877-3536or email [email protected].